Insider Transactions in Q1 2021 at Bio Xcel Therapeutics, Inc. (BTAI)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2021
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,000
-10.32%
|
$720,000
$48.89 P/Share
|
|
Feb 17
2021
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
25,000
-53.71%
|
$1,375,000
$55.51 P/Share
|
|
Feb 17
2021
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+39.29%
|
$125,000
$5.71 P/Share
|
|
Feb 16
2021
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,000
-2.59%
|
$870,000
$58.53 P/Share
|
|
Feb 01
2021
|
Richard I Steinhart Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,750
-71.43%
|
$180,000
$48.15 P/Share
|
|
Feb 01
2021
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+41.67%
|
$18,750
$5.55 P/Share
|
|
Jan 25
2021
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,000
-3.82%
|
$720,000
$48.07 P/Share
|
|
Jan 25
2021
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.67%
|
$0
$0.41 P/Share
|
|
Jan 19
2021
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
25,000
-59.4%
|
$1,250,000
$50.4 P/Share
|
|
Jan 19
2021
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$0
$0.41 P/Share
|